A Multicenter, Randomized, Open-label Trial to Compare Bone Mineral Density and Fat Free Mass in Men GivenReceiving Either Goserelin Acetate (ZOLADEXTM) 10.8- mg Depot or Bicalutamide (CASODEXTM) 150 mg for Treatment of Prostate Cancer.
Study identifier:7054US/0004
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Multicenter, Randomized, Open-label Trial to Compare Bone Mineral Density and Fat Free Mass in Men GivenReceiving Either Goserelin Acetate (ZOLADEXTM) 10.8- mg Depot or Bicalutamide (CASODEXTM) 150 mg for Treatment of Prostate Cancer.
Medical condition
prostate cancer
Phase
Phase 4
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Mar 1998
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
